title: Discontinuation of perioperative antiplatelet and anticoagulant therapy in stroke patients.
abstract: Growing evidence suggests that perioperative withdrawal of ASA for secondary stroke prevention increases thromboembolic risk without the associated benefit of decreased bleeding complications. ASA maintenance is acceptable in many procedures, including invasive ones. Many procedures, in particular ophthalmologic, dermatologic, and dental surgeries, also are safe while continuing oral AC. Warfarin has been continued successfully even in some surgeries that have high bleeding risk. When the risk is too high, temporary bridging therapy with LWMH is safe in many populations. Although the exact thromboembolic risks associated with temporary cessation of AP and AC are unknown and likely low, morbidity and mortality associated with thromboembolism are high. Further studies investigating the risks and benefits of maintaining AP and AC during procedures, particularly invasive ones, are needed. Meanwhile, it is critical that physicians understand the risks and benefits of perioperative AP and AC and the variety of procedures in which these agents can be safely continued.
authors.affiliation: Department of Neurology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. marmstr@lumc.edu
authors.forename: Melissa J
authors.initials: MJ
authors.lastname: Armstrong
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Schneck
authors.forename: José
authors.initials: J
authors.lastname: Biller
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D019990:Perioperative Care; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment; D020521:Stroke / Q000517:prevention & control*; D013923:Thromboembolism / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors